A recent study has found concerns about fertility stop one third of young women with breast cancer from taking tamoxifen despite its known benefit in reducing the risk of breast cancer returning.
The study, which was published in the Journal of the National Cancer Institute also found one quarter of women who started taking tamoxifen stopped taking it before the recommended treatment period ended.
The Eliminate trial will investigate whether combining two breast cancer treatments before surgery is more effective than one treatment alone for women with large and complex ER+ breast cancer.
New research from two studies has found postmenopausal patients with early stage breast cancer who take two types of drugs, aromatase inhibitors (such as Letrozole or Anastrozole) together with bisphosphonates, have better survival rates than those who don’t.
Results from the two studies were collated by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) group in the UK and published recently in The Lancet medical journal.
The latest innovation in fighting cancer has come to New Zealand and will be trialled in breast cancer patients from this month.
Immunotherapy, which is being used successfully to treat patients with melanoma, will now be trialled in patients with Triple Negative Breast Cancer (TNBC), a rare and aggressive form of breast cancer.
An Auckland woman has considered selling her house to try and pay for the breast cancer medicine, Kadcyla, that will keep her alive. The same breast cancer medicine would be available free through the public health system if she lived in Australia.
“We have looked into selling and moving to the outer suburbs but it’s still very expensive. My husband is still working so we can’t leave Auckland,” says Jyoti (Jo) Bhagat.
The Breast Cancer Aotearoa Coalition (BCAC) welcomes news of the government’s new national cancer information strategy which is set to improve access to cancer information nationwide.
BCAC met with the Ministry of Health’s Cancer Team earlier this month for an update on issues raised in our Ministerial Briefing in March. We were pleased to hear that good progress has been made in breast reconstruction and the provision of fertility services. However, we remain concerned about inadequate funding for new medicines and inconsistencies among DHBs in offering lymphoedema services.
Tracey Eising knows that the medicine she is taking to stop her cancer spreading will soon stop working. The only medicine left with a chance of extending her life is Kadcyla, a drug that is currently unfunded in New Zealand. At a cost of $100,000 per year of treatment, Tracey, like most New Zealanders cannot afford it.